Recent 8-K filings for CTXR

• June 1, 2026, 4:30 PM ET other material materiality 0.50 positive item 8.01item 9.01

  Citius Oncology reports Phase 1 combo data: 24% ORR, 33% in endometrial cancer; Phase 2 planned

  Phase 1 trial of LYMPHIR + pembrolizumab in 25 heavily pre-treated gynecologic cancer patients showed 24% ORR (5 partial responses); median duration of response not reached.

• May 15, 2026, 4:41 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Citius Pharma Q2 2026: $5.6M H1 LYMPHIR revenue, 80% gross margins; raises $36.5M at Citius Oncology

  Net product revenue $1.7M in Q2 (launch quarter); $5.6M in H1 2026 vs. zero a year ago.

• May 8, 2026, 7:59 PM ET debt materiality 0.50 neutral item 1.01item 9.01 ◈ Material Agreements

  Citius Pharma subsidiary amends $3.8M note, adds conversion at $0.90, subordinates to senior debt

  Third Amendment to Promissory Note dated May 4, 2026, between Citius Oncology and Citius Pharmaceuticals.

• April 29, 2026, 7:59 PM ET other material materiality 0.70 positive item 3.02item 1.01item 8.01item 9.01

  Citius Oncology ships first international order of LYMPHIR to Europe

  First international shipment of LYMPHIR (denileukin diftitox-cxdl) to Europe through a regional distribution partner.

• April 24, 2026, 7:59 PM ET other material materiality 0.50 neutral item 1.01item 9.01 ◈ Material Agreements

  Citius Pharma raises $5M via registered direct offering and private placement

  Sold 5,076,143 shares/pre-funded warrants at $0.985 each; raised ~$5M gross, $4.5M net.

• April 6, 2026, 7:59 PM ET other materiality 0.15 neutral item 5.07

  Citius shareholders elect seven directors, ratify auditor at 2026 annual meeting

  All seven director nominees elected: Mazur, Holubiak, Dutia, Holuka, McGrath, Smith, Webb.

• March 31, 2026, 7:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Citius Oncology reports early LYMPHIR launch momentum with 83% of target accounts in formulary review

  83% of target accounts have added or are actively progressing LYMPHIR through formulary review.

• March 10, 2026, 7:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Citius Pharmaceuticals reports positive Phase 1 topline results for LYMPHIR/pembrolizumab combo in gynecologic cancers

  Phase 1 trial of LYMPHIR plus KEYTRUDA in 25 evaluable patients with relapsed/refractory gynecologic cancers showed 24% objective response rate and 48% clinical benefit rate.

• March 4, 2026, 6:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Citius subsidiary reports Phase 1 data: LYMPHIR + CAR-T shows 86% ORR, 57% CR in high-risk DLBCL

  ORR 86% at 1 month (57% CR, 29% PR) in 14 patients with relapsed/refractory DLBCL.

• February 13, 2026, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 3.01item 9.01 ◈ Listing & Compliance Notices

  Citius Pharma posts first revenue of $3.9M from LYMPHIR launch; Nasdaq warns of bid price deficiency

  Q1 FY2026 revenue $3.9M from initial LYMPHIR sales; net loss $8.2M ($0.41 loss per share).

• December 23, 2025, 6:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01

  Citius Pharma reports FY2025 net loss $39.7M; launches LYMPHIR in December 2025

  Net loss $39.7M ($3.38/share) vs $40.2M ($5.97/share) prior year; no revenue.

• December 1, 2025, 6:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Citius Oncology launches LYMPHIR for CTCL; first marketed product

  LYMPHIR (denileukin diftitox-cxdl) now commercially available in U.S. for relapsed/refractory Stage I–III CTCL after prior systemic therapy.

• October 23, 2025, 7:59 PM ET other material materiality 0.30 neutral item 7.01item 9.01

  Citius Pharmaceuticals updates corporate presentation; reiterates LYMPHIR Q4 2025 launch and pipeline progress

  LYMPHIR (denileukin diftitox-cxdl) FDA approved for CTCL; commercial launch planned Q4 2025.

• October 21, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 9.01

  Citius Pharmaceuticals raises $6.0M in registered direct offering for LYMPHIR launch

  Gross proceeds ~$6.0M; net ~$5.5M after placement agent fees and expenses.

• August 12, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Citius Pharma Q3 fiscal 2025 net loss narrows to $9.2M; LYMPHIR launch on track for Q4

  Net loss of $9.2M ($0.80 per share) vs $10.6M ($1.57 per share) in the prior-year quarter.

• July 8, 2025, 7:59 PM ET other material materiality 0.50 neutral item 8.01item 9.01

  Citius regains compliance with Nasdaq minimum bid price requirement

  Nasdaq confirmed compliance with Listing Rule 5550(a)(2) after 10 consecutive trading days with bid price at $1.00 or greater.

• June 12, 2025, 7:59 PM ET other material materiality 0.55 neutral item 1.01item 9.01

  Citius Pharma closes $6M registered direct offering with warrants for up to $9.8M additional proceeds

  Gross proceeds of $6M from sale of 4.92M shares/pre-funded warrants at $1.22 per share.

• June 9, 2025, 7:59 PM ET other material materiality 0.50 neutral item 3.03item 5.03item 5.07item 9.01 ◈ Governance Changes

  Citius Pharmaceuticals increases authorized shares 10x, redeems Series A Preferred for $100

  Authorized shares increased from 26M to 260M; common shares from 16M to 250M.

• June 3, 2025, 7:59 PM ET debt materiality 0.55 neutral item 1.01item 2.03item 9.01 ◈ Debt Financings

  Citius Pharma issues $1M unsecured note at 15% interest; CEO personally guarantees

  $1M principal unsecured promissory note issued to Pagoda Resources on June 2, 2025.

• May 30, 2025, 7:59 PM ET regulatory materiality 0.75 negative item 3.01

  Citius Pharma receives Nasdaq delisting notice for bid price non-compliance

  Received Nasdaq letter on May 29, 2025 for failing minimum $1 bid price for 33 consecutive business days.

• May 14, 2025, 7:59 PM ET earnings materiality 0.85 negative item 2.02item 9.01

  Citius Pharma Q2 net loss $11.5M; cash only $26K; needs capital beyond May 2025

  Net loss of $11.5M ($1.27 per share) for Q2 fiscal 2025 vs $8.5M a year ago.

• April 18, 2025, 7:59 PM ET other material materiality 0.55 neutral item 1.01item 5.03item 3.02item 3.03item 9.01

  Citius issues CEO super-voting stock to push 16M-to-250M share increase; quorum cut to 1/3

  One share of Series A Preferred sold to CEO Leonard Mazur for $100 with 1B votes, valid only on proposed authorized share increase from 16M to 250M common shares.

• April 3, 2025, 7:59 PM ET debt materiality 0.60 neutral item 1.01item 9.01

  Citius Oncology amends license agreement with Eisai, defers $8.2M in LYMPHIR payments to 2025

  Total obligations owed to Eisai: $8,233,209.77 including $5.9M milestone and $2.33M development/inventory costs.

• April 2, 2025, 7:59 PM ET other material materiality 0.55 neutral item 1.01item 9.01

  Citius Pharma raises $2M in registered direct offering; proceeds for LYMPHIR launch

  Offering of 465,000 shares at $1.15 and 1,274,131 pre-funded warrants at $1.1499.

• March 10, 2025, 7:59 PM ET other material materiality 0.15 negative item 5.07

  Citius shareholders defeat share-increase proposal, elect all director nominees

  Proposal to raise authorized shares from 26M to 260M failed with 3,222,490 for vs. 1,934,414 against.

• February 14, 2025, 6:59 PM ET earnings materiality 0.75 negative item 8.01item 2.02item 9.01

  Citius Pharma Q1 2025 net loss $10.3M; prepares LYMPHIR launch H1 2025

  Net loss of $10.3M ($1.30 per share) vs. $9.2M ($1.45) in Q1 2024; cash $1.1M as of Dec 31, 2024.

• February 6, 2025, 6:59 PM ET regulatory materiality 0.60 positive item 8.01item 9.01

  Citius Pharma receives permanent J-code J9161 for LYMPHIR, effective April 1, 2025

  CMS assigned permanent HCPCS J-code J9161 to LYMPHIR (denileukin diftitox-cxdl) for CTCL.

• January 8, 2025, 6:59 PM ET other material materiality 0.65 neutral item 1.01item 9.01

  Citius Pharma raises ~$3M in registered direct offering of stock and warrants

  Offering of 743,496 shares plus warrants for 743,496 shares at combined price of $4.035 per unit.

• January 7, 2025, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Citius Pharma reports LYMPHIR launch prep progress; targeting H1 2025 commercial launch

  LYMPHIR approved Aug 2024 for relapsed/refractory CTCL; commercial launch targeted H1 2025.

• December 27, 2024, 6:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Citius Pharma reports FY 2024 net loss of $39.4M; FDA approval of LYMPHIR highlights

  Net loss $39.4M ($5.97/share) for FY ended Sep 30, 2024 vs $32.5M ($5.57) prior year.

• December 20, 2024, 6:59 PM ET regulatory materiality 0.65 positive item 8.01

  Citius Pharmaceuticals regains Nasdaq compliance on bid price rule

  Received Nasdaq notice on Dec 18, 2024 confirming compliance with Listing Rule 5550(a)(2).

• November 26, 2024, 6:59 PM ET other material materiality 0.55 neutral item 3.03item 5.03item 8.01item 9.01

  Citius Pharmaceuticals effects 1-for-25 reverse stock split to regain Nasdaq bid price compliance

  Reverse split at 1-for-25 ratio effective Nov 25, 2024; split-adjusted trading begins Nov 26.

• November 25, 2024, 6:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  Citius Pharmaceuticals Reports Productive FDA Type C Meeting for Mino-Lok Phase 3 Program

  Citius Pharma held a constructive in-person Type C meeting with the FDA on November 25, 2024, regarding its Phase 3 Mino-Lok trial for catheter-related bloodstream infections.

• November 18, 2024, 6:59 PM ET other material materiality 0.65 neutral item 1.01item 9.01

  Citius Pharma raises $3M in registered direct offering of 12M shares and 12M warrants

  Offering consists of 12M common shares and warrants for 12M shares at combined $0.25; gross proceeds $3.0M.

• November 13, 2024, 6:59 PM ET regulatory materiality 0.60 neutral item 3.01

  Nasdaq panel grants Citius Pharma extension to regain bid price compliance by Dec 3, 2024

  Company received bid price deficiency notice on Sep 12, 2023, extended to Sep 9, 2024.

• November 12, 2024, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Citius reports 27% ORR in Phase I trial of pembrolizumab + LYMPHIR for recurrent solid tumors

  27% objective response rate (4/15) and 33% clinical benefit rate; median PFS 57 weeks for patients with clinical benefit.

• September 27, 2024, 7:59 PM ET other material materiality 0.20 neutral item 1.01

  Citius extends employment agreement with EVP Holubiak and insider warrants to 2025

  Myron Holubiak's employment term extended by one year to Oct 31, 2025; all other terms unchanged.

• September 13, 2024, 7:59 PM ET other material materiality 0.50 neutral item 1.01

  Citius Pharma obtains partial deferral of milestone payment to Dr. Reddy's under LYMPHIR deal

  Dr. Reddy's agreed to partial deferral without penalty of a milestone payment due Sep 9, 2024.

• September 11, 2024, 7:59 PM ET regulatory materiality 0.80 negative item 3.01

  Citius Pharma receives Nasdaq delisting determination for bid price non-compliance; plans hearing

  Received delisting determination on Sept 10, 2024 after failing to regain $1.00 bid price compliance by extended deadline of Sept 9, 2024.

• September 5, 2024, 7:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  LYMPHIR added to NCCN Guidelines for CTCL treatment

  NCCN Category 2A recommendation supports LYMPHIR as option for relapsed/refractory CTCL after at least one prior systemic therapy.

• August 16, 2024, 7:59 PM ET M&A materiality 0.85 positive item 1.01item 2.03item 8.01item 9.01

  Citius Pharma completes SPAC merger, forms Citius Oncology; holds ~90% of new public company

  Merger closed Aug 12, 2024; Citius Oncology expected to trade on Nasdaq as CTOR on Aug 13.

• August 12, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Citius Pharma Q3 net loss $10.6M; FDA approves LYMPHIR, oncology spin-off begins trading

  FDA approved LYMPHIR (denileukin diftitox-cxdl) for cutaneous T-cell lymphoma on Aug 12, 2024.

• August 8, 2024, 7:59 PM ET regulatory materiality 0.95 positive item 8.01item 9.01

  Citius Pharma receives FDA approval for LYMPHIR (denileukin diftitox-cxdl) in r/r CTCL

  Phase 3 study showed 36.2% ORR, 8.7% complete response, median time to response 1.41 months.

• May 21, 2024, 7:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  Citius Pharma: Mino-Lok Phase 3 trial meets primary endpoint (p=0.0006) in CLABSI/CRBSI

  Primary endpoint: time to catheter failure significantly delayed for Mino-Lok vs control (p=0.0006); hazard ratio 0.53.

• May 14, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Citius Pharma Q2 net loss $8.5M; LYMPHIR PDUFA Aug 13, Mino-Lok data due Q2

  Cash $12.6M at Mar 31; $15M April offering extends runway through Dec 2024.

• April 30, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 9.01 ◈ Material Agreements

  Citius Pharma raises ~$15M in registered direct offering of common stock and warrants

  Sold 21.43M shares and warrants to buy 21.43M shares at $0.70/combined unit.

• April 5, 2024, 7:59 PM ET other material materiality 0.25 neutral item 8.01

  Citius extends CEO/EVP warrants to April 5, 2025; exercise would yield $2.3M

  Board approved one-year extension for 1,294,498 Investor Warrants held by CEO Leonard Mazur and EVP Myron Holubiak, exercise price $1.42 each.

• March 18, 2024, 7:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  Citius Pharma: FDA accepts BLA resubmission for LYMPHIR (CTCL); PDUFA Aug 13, 2024

  FDA accepted BLA resubmission for LYMPHIR (denileukin diftitox) to treat relapsed/refractory cutaneous T-cell lymphoma.

• March 13, 2024, 7:59 PM ET other material materiality 0.70 negative item 3.01item 5.07 ◈ Shareholder Votes ×2◈ Listing & Compliance Notices

  Citius Pharma gets Nasdaq bid-price compliance extension to Sept 9, 2024; annual meeting elects directors

  Nasdaq granted extension until Sept 9, 2024 to regain $1.00 minimum bid price; stock continues trading under CTXR.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.95 · Median 0.65 · Most common event other_material

18 positive 8 negative 23 neutral

source · CTXR on sec.gov